We report that these new analogs show strong anti-proliferative potency against human melanoma and colorectal cancer cells, effectively overcome P-gp mediated drug resistance, and maintain their mechanisms of action by selectively inhibiting survivin expression and inducing cancer cell apoptosis. Here, BIRC5 is linked to cancer.